Please login to the form below

Not currently logged in
Email:
Password:

ThromboGenics

This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

It is also good news for the drug's original developers ThromboGenics, which sold non-US rights for Jetrea to Novartis in 2012 in a deal worth up to 375m, and ... progressive disease much earlier and  as soon as patients  start experiencing symptoms

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief ... Patrik De Haes, chief executive officer,

  • ThromoboGenics appoints Thomas Clay as chairman of the board ThromoboGenics appoints Thomas Clay as chairman of the board

    He moves from his previous position as non-executive director. Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf ... Clay has been a non-executive director of

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics